Skip to main content
New research, published by Wiley, shows that Black men in the United States are more likely to develop prostate cancer than white men. Furthermore, after diagnosis, Black men are more likely to have advanced disease and to die than white men with the disease.
The researchers say that although it would seem that earlier prostate‐specific antigen (PSA) screening could reduce the risk of fatal prostate cancer in Black men, new research indicates that at any given PSA level, Black men are more likely to harbor prostate cancer than white men.

This indicates that they may face an increased risk of prostate cancer than white men at lower PSA levels. The findings were published by Wiley in CANCER, a peer-reviewed journal of the American Cancer Society.

What the study reveals about Black men and prostate cancer

For the study, researchers used models to predict the likelihood of prostate cancer diagnosis from a first biopsy for 75,295 Black and 207,658 white male veterans receiving care from the U.S. Department of VeteransAffairs (VA). Prostate cancer was detected in the first prostate biopsy in 55% of Black men and in 43% of white men.

After taking various competing factors into account, Black Veterans were 50% more likely to receive a prostate cancer diagnosis based on their first prostate biopsy than white veterans.

Understanding PSA levels and risk

Also, Black men with a pre-biopsy PSA of 4.0 ng/mL had a 49% risk of prostate cancer detected during their biopsy, compared with a 39% risk for white men with the same PSA level. The investigators’ model indicated that Black Veterans with a PSA of 4.0 ng/mL had an equivalent risk of prostate cancer as white Veterans with a PSA of 13.4 ng/mL.

“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age.

Clinicians may consider earlier screening for populations at greater than average risk, which includes Black men,” said first author Kyung Min Lee, PhD.  Min Lee hails from the VA Informatics and Computing Infrastructure (VINCI), located within the VA Salt Lake City Health Care System.

Why prostate screening with PSA should be individualized

The VA recommends that, for the average risk of men ages 55–69 years, any decision to initiate or continue prostate cancer screening with PSA should be individualized.  Jane Kim, MD, MPH, Executive Director for Preventive Medicine at the VA explained:

“This includes consideration of age, family history, race/ethnicity, medical conditions, and patient values, as well as potential benefits versus harms.

Per the U.S. Preventive Services Task Force, before deciding whether to be screened, men should have an opportunity to discuss the benefits and harms of screening through shared decision making with their clinicians.” 

Bottom line

Dr. Lee added that prospective studies are needed to evaluate the risks and benefits of lower PSA biopsy thresholds informed by patient race and genetic risk scores. 

“The VA Office of Research & Development has recently initiated the ProGRESS clinical trial—The Prostate Cancer, Genetic Risk, and Equitable Screening Study—to evaluate these questions,” he said.

References and Full Citation:

“Association between prediagnostic PSA and prostate cancer probability in Black and non‐Hispanic White men.” Kyung Min Lee, Alex K. Bryant, Julie A. Lynch, Brian Robison, Patrick R. Alba, Fatai Y. Agiri, Kathryn M. Pridgen, Scott L. DuVall, Kosj Yamoah, Isla P. Garraway, and Brent S. Rose. CANCER; Published Online: November 6, 2023 (DOI:10.1002/cncr.34979).  URL Upon Publication: http://doi.wiley.com/10.1002/cncr.34979 

About the Journal

CANCERis a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties.

The objective ofCANCERis to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer.CANCERis published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on Twitter and Instagram, and stay up to date with the American Cancer Society Journals on LinkedIn.

About Wiley

Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world’s most important challenges.

For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Follow them onFacebook, Twitter,LinkedIn, and Instagram.

Em Sloane

Em Sloane

I am an introverted nature lover, and long time contributor to LongevityLive.com. My role is to publish the information in a consumer friendly format, which we receive on the latest medical news, press releases and general information on the latest longevity related research findings.

Longevity Live is a digital publisher AND DOES NOT OFFER PERSONAL HEALTH OR MEDICAL ADVICE. IF YOU’RE FACING A MEDICAL EMERGENCY, CALL YOUR LOCAL EMERGENCY SERVICES IMMEDIATELY, OR VISIT THE NEAREST EMERGENCY ROOM OR URGENT CARE CENTER. YOU SHOULD CONSULT YOUR HEALTHCARE PROVIDER BEFORE STARTING ANY NUTRITION, DIET, EXERCISE, FITNESS, MEDICAL, OR WELLNESS PROGRAM.

This content, developed through collaboration with licensed medical professionals and external contributors, including text, graphics, images, and other material contained on the website, apps, newsletter, and products (“Content”), is general in nature and for informational purposes only and does not constitute medical advice; the Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Always consult your doctor or other qualified healthcare provider with any questions you may have regarding a medical condition, procedure, or treatment, whether it is a prescription medication, over-the-counter drug, vitamin, supplement, or herbal alternative.

Longevity Live makes no guarantees about the efficacy or safety of products or treatments described in any of our posts. Any information on supplements, related services and drug information contained in our posts are subject to change and are not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.

Longevity does not recommend or endorse any specific test, clinician, clinical care provider, product, procedure, opinion, service, or other information that may be mentioned on Longevity’s websites, apps, and Content.

error: Content is protected !!